Loading viewer...
investor_presentation
Format: PDF investor_presentation
Investor RelationsOctober 27, 2020Fourth Quarter Fiscal Year 2020
Investor RelationsOctober 27, 2020Fourth Quarter
This presentation is intended exclusively for investors.
It is not intended for use in Sales or Marketing.
Forward -Looking Statements
Except forhistorical information, thispresentation contains forward -looking statements within themeaning ofthePrivate Securities Litigation Reform Actof1995 .Statements concerning thetiming ofthecompany's
acquisition bySiemens Healthineers ,thecompany’s long-term growth andvalue creation strategies, future orders, backlog, liquidity, capital allocation priorities andtheanticipated impact oftheCOVID -19pandemic onour
business ;andanystatements using theterms “could,” “believe,” “expect,” “promising,” “outlook,” “should,” “well-positioned,” “will” orsimilar statements areforward -looking statements thatinvolve risks anduncertainties
thatcould cause thecompany’s actual results todiffer materially from those anticipated .Such risks anduncertainties include thefuture impact oftheCOVID -19pandemic onourbusiness, including butnotlimited to,the
impact onourworkforce, operations, supply chain, demand forourproducts andservices, andourfinancial results andcondition ;ourability tosuccessfully manage thechallenges associated withtheCOVID -19pandemic ;
ourability toachieve expected synergies from acquisitions ;risks associated withintegrating recent acquisitions ;global economic conditions andchanges totrends forcancer treatment regionally ;currency exchange rates
andtaxrates ;theimpact oftheTaxCuts andJobs Act;theimpact oftheAffordable Health Care forAmerica Act(including excise taxes onmedical devices) andanyfurther healthcare reforms (including changes to
Medicare andMedicaid), and/or changes inthird-party reimbursement levels ;recent andpotential future tariffs, cross -border trade restrictions oraglobal trade war;demand foranddelays indelivery ofthecompany’s
products ;thecompany’s ability todevelop, commercialize anddeploy new products ;thecompany’s ability tomeet Food andDrug Administration (FDA) andother regulatory requirements, regulations orprocedures ;
changes inregulatory environments ;risks associated with thecompany providing financing fortheconstruction and start-upoperations ofparticle therapy centers, challenges associated with commercializing the
company’s proton solutions business ;challenges topublic tender awards andtheloss ofsuch awards orother orders ;theeffect ofadverse publicity ;thecompany’s reliance onsole orlimited -source suppliers ;the
company’s ability tomaintain orincrease margins ;theimpact ofcompetitive products and pricing ;thepotential loss ofkeydistributors orkeypersonnel ;challenges related toentering intonew business lines;the
occurrence ofanyevent, change orother circumstances thatcould give risetothetermination ofthemerger agreement withSiemens Healthineers ;thefailure toobtain certain required regulatory approvals orthefailure to
Preview truncated — download the full document for the complete content.
conference
27 Pages
investor_presentation
23 Pages
Veeco Instruments Inc.
Cloopen Group RAAS 2021 Q1 Investor Presentation
investor_presentationinvestor_presentation
12 Pages
Cloopen Group Holding Limited